Diet, exercise and smoking cessation are all known to lower hsCRP levels and are first-line interventions recommended for the general population to reduce the risk of heart attack and stroke. However, until now, no large, prospective data study has shown that any pharmacologic therapy given to those without elevated cholesterol levels but with elevated hsCRP could prevent cardiovascular events.
Since statins lower both LDL cholesterol and hsCRP (used as a marker of inflammation), the findings presented at the meeting cannot determine whether cholesterol lowering, a reduction in inflammation, or a combination of both are responsible for the reductions seen.
Other co-authors are: Eleanor Danielson, B.A.; Francisco Fonseco, M.D.; Jacques Genest, M.D.; Antonio M. Gotto, M.D.; John J.P. Kastelein, M.D., Ph.D.; Wolfgang Koenig, M.D.; Peter Libby, M.D.; Alberto Lorenzatti, M.D.; Jean MacFadyen, B.A.; Borge G. Nordestgaard, M.D.; James Shepherd, M.D.; James T. Willerson, M.D.; and Robert J. Glynn, Ph.D. Individual author disclosures are available on the abstract.
The study was sponsored by AstraZeneca.
Statements and conclusions of study authors that are presented at
American Heart Association scientific meetings are solely those of the
study authors and do not necessarily reflect association policy or
position. The association makes no representation or warranty as to their
accuracy or reliability. The association receives funding primarily from
individuals; foundations and corporations (including pharmaceutical, device
manufacturers and other companies) also make donations and fund specific
association programs and events. The association has strict policies to
prevent these relationships from influencing the science content. Revenues
from pharmaceutical and device corporations ar
|SOURCE American Heart Association|
Copyright©2008 PR Newswire.
All rights reserved